Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 2342-2352

  Jones, Jon ^a   Juengel, Eva ^a   Mickuckyte, Ausra ^a   Hudak, Lukasz ^a   Wedel, Steffen ^a   Jonas, Dietger ^a   Hintereder, Gudrun ^a   Blaheta, Roman A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Adhesion; HDAC; Integrin receptors; Renal cell carcinoma; Valproic acid

Indexed keywords

VALPROIC ACID;

ARTICLE; CELL ADHESION; DRUG EFFECT; ENDOTHELIUM; EXTRACELLULAR MATRIX; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL ADHESION; CELL LINE, TUMOR; ENDOTHELIUM; EXTRACELLULAR MATRIX; HUMANS; KIDNEY NEOPLASMS; VALPROIC ACID;

EID: 72949123264     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00603.x     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005 55 : 74 108.
2. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol. 2006 33 : 576 582.
3. Oudard S, George D, Medioni J, et al. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol. 2007 18S : x25 x31.
4. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther. 2004 4 : 455 468.
5. Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis. 2008 25 : 183 189.
6. Cinatl J Jr., Cinatl J, Scholz M, et al. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs. 1996 7 : 766 773.
7. Blaheta RA, Michaelis M, Driever PH, et al. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev. 2005 25 : 383 397.
8. Jones J, Juengel E, Mickuckyte A, et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo J Cell Mol Med. 2009 8A : 2376 2385.
9. Michaelis M, Suhan T, Cinatl J, et al. Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol. 2004 25 : 1795 1799.
10. Cinatl J Jr., Kotchetkov R, Blaheta R, et al. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol. 2002 20 : 97 106.
11. Kuljaca S, Liu T, Tee AE, et al. Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol Cancer. 2007 6 : 68.
12. Xia Q, Sung J, Chowdhury W, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006 66 : 7237 7244.
13. Moschos SJ, Drogowski LM, Reppert SL, et al. Integrins and cancer. Oncology. 2007 21 : 13 20.
14. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta. 2007 1775 : 163 180.
15. Steinbach F, Tanabe K, Alexander J, et al. The influence of cytokines on the adhesion of renal cancer cells to endothelium. J Urol. 1996 155 : 743 748.
16. Jin JS, Hsieh DS, Lin YF, et al. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol. 2006 13 : 573 580.
17. Qian DZ, Kachhap SK, Collis SJ, et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006 66 : 8814 8821.
18. Blaheta RA, Michaelis M, Natsheh I, et al. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer. 2007 96 : 1699 1706.
19. Beecken WD, Engl T, Ogbomo H, et al. Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells. Int Immunopharmacol. 2005 5 : 757 769.
20. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004 5 : 816 826.
21. Moschos SJ, Drogowski LM, Reppert SL, et al. Integrins and cancer. Oncology. 2007 21S : 13 20.
22. Markovic-Lipkovski J, Brasanac D, Muller GA, et al. Cadherins and integrins in renal cell carcinoma: an immunohistochemical study. Tumori. 2001 87 : 173 178.
23. Jones J, Berkhoff S, Weich E, et al. Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes. J Cell Mol Med. 2007 11 : 826 838.
24. Winterwood NE, Varzavand A, Meland MN, et al. A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell. 2006 17 : 2707 2721.
25. Skalski M, Coppolino MG. SNARE-mediated trafficking of alpha5beta1 integrin is required for spreading in CHO cells. Biochem Biophys Res Commun. 2005 335 : 1199 1210.
26. Powelka AM, Sun J, Li J, et al. Stimulation-dependent recycling of integrin beta1 regulated by ARF6 and Rab11. Traffic. 2004 5 : 20 36.
27. Hauck CR, Sieg DJ, Hsia DA, et al. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res. 2001 61 : 7079 7090.
28. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000 2 : 249 256.
29. Satoh M, Nejad FM, Ohtani H, et al. Association of renal cell carcinoma antigen, disialylgalactosylgloboside, with c-Src and Rho A in clustered domains at the surface membrane. Int J Oncol. 2000 16 : 529 536.
30. Jones J, Marian D, Weich E, et al. CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp Cell Res. 2007 313 : 4051 4065.
31. Lee JC, Maa MC, Yu HS, et al. Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells. Mol Carcinog. 2005 43 : 207 214.
32. Shabbeer S, Kortenhorst MS, Kachhap S, et al. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate. 2007 67 : 1099 1110.
33. Gao D, Xia Q, Lv J, et al. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo. Int J Urol. 2007 14 : 838 845.
34. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist. 2007 12 : 942 951.
35. Yang Q, Tian Y, Liu S, et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res. 2007 67 : 1716 1724.
36. Yamamoto-Yamaguchi Y, Okabe-Kado J, Kasukabe T, et al. Induction of apoptosis by combined treatment with differentiation-inducing agents and interferon-alpha in human lung cancer cells. Anticancer Res. 2003 23 : 2537 2547.
37. Kaneko F, Saito H, Saito Y, et al. Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int J Oncol. 2004 24 : 837 845.
38. Krämer OH, Baus D, Knauer SK, et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 2006 20 : 473 485.
39. Wong LH, Sim H, Chatterjee-Kishore M, et al. Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1. J Biol Chem. 2002 277 : 19408 19417.